Business Wire

CA-ALKIRA

27.4.2022 13:02:08 CEST | Business Wire | Press release

Share
Alkira Launches Free Tool to Tame Cloud Bloat

Cloud networking pioneer Alkira today launched Cloud Insights, a free tool to improve the networking and security of enterprise cloud deployments. Nearly a third (32%) of cloud spending is wasted, according to Flexera’s State of the Cloud Report 2022, which identifies optimization of existing cloud resources as the top priority for enterprises.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220427005119/en/

Cloud spending and network complexity accelerated during the pandemic, putting further pressure on businesses to optimize their cloud deployments. Growth shows no sign of slowing this year, as IDC forecasts a 21.7% increase in cloud infrastructure spending for the rest of 2022.

Alkira Cloud Insights helps cloud architects and networking admins regain control of their cloud infrastructure. The tool provides tailored recommendations on how to improve security, optimize spend and boost cloud networking performance in Amazon AWS and Microsoft Azure environments. It can help uncover duplicate IP addresses, unsanctioned internet access, unused networks and security resources, misconfigured security group settings, and unaccounted for shadow IT resources, among other things.

“Many organizations dramatically increased their cloud deployments at the beginning of Covid to support remote work and digital transformation,” said Amir Khan, CEO and founder of Alkira. “Because the shift was so sudden, many organizations' initial focus was on just making things work; the deployments were far from optimized. Alkira Cloud Insights allows businesses to do what equates to a bit of ‘spring cleaning’ for their environments. The tool helps to streamline cloud deployments, improve security posture and eliminate costly waste.”

Cloud Insights performs a rapid discovery of an organization’s AWS and Azure cloud networking environments. Companies will get a complete and automated inventory of their networking and security resources. They’ll also receive actionable data, including recommendations to improve cloud usage, security and spend. The insights and findings are delivered in an easy to use, centralized dashboard. There is also the ability to configure automated reporting to keep up to date on dynamic changes made to the cloud network environment.

Brad Casemore, Research Vice President, Datacenter and Multicloud Networks, IDC, said: “Networks that enable and support hybrid and multicloud should be sufficiently intelligent to perform optimally across an increasingly distributed landscape of cloud workloads and end points. But it all starts with meaningful audit and discovery, determining and understanding what workloads are running in which clouds, and providing insight into the networks and security postures associated with those workloads.

“Only with that foreknowledge can enterprises gain actionable insights that yield valuable business benefits and outcomes. With Cloud Insights, Alkira offers customers a free tool that helps to provide a foundational understanding of their cloud environments, setting the stage for informed enhancements that improve the agility, efficiency, performance, resiliency, and security of cloud networking.”

Existing customers get immediate access to Cloud Insights through the Alkira portal. The company is also making it freely available at https://www.alkira.com/cloud-insights to other enterprise teams looking for a quicker and easier way to audit their cloud estate.

About Alkira

Alkira is the leader in cloud networking as a service . We unify multiple clouds, sites, and users via an enterprise network built entirely in the cloud. Our Cloud Exchange Points auto-create this network plumbing and when deployed to multiple locations auto-connect to form a global fabric – all done with point and click integration of best-of-breed security and networking services. The network is managed using the same controls, policies, and security network admins know, can instantly scale as needed, and is available as a service. There is no new hardware to deploy, no software to download and no cloud architecture to learn. Alkira’s solution is trusted by Fortune 100 enterprises, leading system integrators and global managed service providers. Learn more at alkira.com and follow us @alkiranet .

Video Tour: https://youtu.be/jBQipdute44

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye